The FDA will consider a supplemental new drug application for deucravacitinib for the treatment of adults with active psoriatic arthritis based on promising results from clinical trials.
A New Treatment for Fibromyalgia?
The FDA has approved a new drug application for TNX-102 SL (Tonmya), a tablet with 2.8 mg of cyclobenzaprine HCl, after two clinical trials demonstrated the safety and effectiveness of the treatment in adults with fibromyalgia.
ACR Advocates for Fair Reimbursement & Telehealth Flexibility in MPFS 2026 Proposed Rule
In comments to the CMS, the ACR advocated for telehealth flexibilities and fair reimbursement and pushed back on proposed efficiency adjustments and changes likely to increase administrative burden on practices.
AMA State Advocacy Roundtable Addresses Pressing Policy Challenges
The roundtable included discussions on emerging issues in state advocacy, prior authorization reform, likely impacts of the Big Beautiful Bill and physician wellness.
ACR Calls on Alaska, Montana to Strengthen Rheumatology Care Through Federal Funding
The new Rural Health Transformation Program offers states the chance to apply for CMS funding aimed at transforming rural healthcare.
What to Expect in Chicago at the Practice Innovation Summit
The Practice Innovation Summit, to be held in Chicago Oct. 24–25, offers a roadmap to a smarter, stronger rheumatology practice, led by experts in operations, coding, financial sustainability and more.
ACR President Warns: Access to Care Is at Risk Without Medicare Payment Reform
In a recent commentary published by Medscape, ACR President Carol Langford, MD, MHS, issues a stark warning: If Congress does not reform the physician payment system, patients may face increasing difficulty accessing essential medical services.
ACR Responds to Threats to Scientific Integrity at the CDC
On Aug. 29, the ACR issued a strong statement expressing deep concern over recent developments at the agency that could threaten the integrity of science-based public health policy.
Cardiovascular Risks Similar for JAK Inhibitors & bDMARDs
Using data from registries across Europe and Canada, Aymon et al. compared the incidence of major adverse cardiac events (MACE) in patients with RA treated with JAK inhibitors, TNF inhibitors or biologic DMARDs with other modes of action over two years. The researchers did not find an increased risk of MACE with JAK inhibitors over that time frame.
Mouth-Watering Possibilities in Sjögren’s Disease
New ACR guidelines for SARD-associated interstitial lung disease cover key recommendations for screening, monitoring and first-line treatment options.
- 1
- 2
- 3
- …
- 325
- Next Page »